Adjustment of bid winning results of anticancer drugs in Jiangxi Province, disqualification of 2 standard based drugs

Recently, Jiangxi announced the "notice on publicizing the adjustment of bidding results of provincial special centralized procurement of anti-cancer drugs in Jiangxi Province", informing China Beijing Yuance Pharmaceutical Co., Ltd that two specifications of recombinant human interferon α 2B for injection were disqualified It is reported that the two specifications are new varieties in the National Essential Drug Catalogue (2018 version) The specific details are as follows: Notice on publicizing the adjustment of bid winning results of provincial-level special centralized procurement of anticancer drugs in Jiangxi Province: according to the implementation plan of provincial-level special centralized procurement of anticancer drugs in Jiangxi Province in 2018, after research and decision, the bid winning results of provincial-level special centralized procurement of anticancer drugs in Jiangxi Province in 2018 are now adjusted The publicity time is from January 16 to January 22, 2019 If there is any objection during the publicity period, please submit the written materials with the official seal of the company to the provincial pharmaceutical purchasing service center before 17:00 on January 22 Notice is hereby given Appendix: adjustment of bidding results of provincial special centralized procurement of anticancer drugs in Jiangxi Province in 2018 table of adjustment of bidding results of provincial special centralized procurement of anticancer drugs in Jiangxi Province on January 16, 2019